WallStSmart

Abbott Laboratories (ABT)vsGlaukos Corp (GKOS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 8086% more annual revenue ($45.13B vs $551.35M). ABT leads profitability with a 13.9% profit margin vs -34.3%. ABT appears more attractively valued with a PEG of 1.32. ABT earns a higher WallStSmart Score of 56/100 (C).

ABT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 4.7Quality: 6.0
Piotroski: 4/9Altman Z: 2.71

GKOS

Hold

44

out of 100

Grade: D

Growth: 10.0Profit: 2.0Value: 4.3Quality: 6.5
Piotroski: 3/9Altman Z: 0.57
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-24.7%)

Margin of Safety

-24.7%

Fair Value

$70.91

Current Price

$90.50

$19.59 premium

UndervaluedFair: $70.91Overvalued
GKOSFair Value (-1.2%)

Margin of Safety

-1.2%

Fair Value

$107.76

Current Price

$131.19

$23.43 premium

UndervaluedFair: $107.76Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT1 strengths · Avg: 9.0/10
Market CapQuality
$154.45B9/10

Large-cap with strong market position

GKOS3 strengths · Avg: 9.7/10
Revenue GrowthGrowth
41.2%10/10

Revenue surging 41.2% year-over-year

EPS GrowthGrowth
1896.0%10/10

Earnings expanding 1896.0% YoY

Debt/EquityHealth
0.159/10

Conservative balance sheet, low leverage

Areas to Watch

ABT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-19.7%2/10

Earnings declined 19.7%

GKOS4 concerns · Avg: 3.3/10
PEG RatioValuation
1.644/10

Expensive relative to growth rate

Price/BookValuation
11.4x4/10

Trading at 11.4x book value

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-28.2%2/10

ROE of -28.2% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap. PEG of 1.32 suggests the stock is reasonably priced for its growth.

Bull Case : GKOS

The strongest argument for GKOS centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 41.2% demonstrates continued momentum.

Bear Case : ABT

The primary concerns for ABT are EPS Growth.

Bear Case : GKOS

The primary concerns for GKOS are PEG Ratio, Price/Book, Piotroski F-Score.

Key Dynamics to Monitor

ABT profiles as a value stock while GKOS is a hypergrowth play — different risk/reward profiles.

GKOS carries more volatility with a beta of 0.81 — expect wider price swings.

GKOS is growing revenue faster at 41.2% — sustainability is the question.

ABT generates stronger free cash flow (916M), providing more financial flexibility.

Bottom Line

ABT scores higher overall (56/100 vs 44/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Glaukos Corp

HEALTHCARE · MEDICAL DEVICES · USA

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, is focused on developing new therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is headquartered in San Clemente, California.

Want to dig deeper into these stocks?